17:56 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Mouse studies suggest inhibiting JNK1 could help treat...
17:40 , Nov 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Cell culture and mouse studies suggest inhibiting JNK1 or its substrate AP-1 could help treat the viral infection Japanese encephalitis (JE). In JE virus-infected human glioma and murine microglial cell lines, a JNK...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes; liver failure c-Jun N-terminal kinase (JNK) In vitro and mouse studies suggest compounds blocking both the ATP- and substrate-binding sites...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Marfan syndrome MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); c-jun N-terminal kinase...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

PregLem, Merck KGaA deal

Merck's Merck Serono S.A. unit granted PregLem exclusive, worldwide rights to develop and commercialize bentamapimod . Merck will receive an upfront payment and is eligible for milestones and royalties. PregLem said it plans to begin...